ProfileGDS5678 / 1456532_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 88% 87% 86% 81% 80% 84% 81% 84% 81% 86% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2608785
GSM967853U87-EV human glioblastoma xenograft - Control 26.3586185
GSM967854U87-EV human glioblastoma xenograft - Control 36.868288
GSM967855U87-EV human glioblastoma xenograft - Control 46.8720887
GSM967856U87-EV human glioblastoma xenograft - Control 56.631586
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6192481
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.565980
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1381784
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7457581
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2443484
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.808481
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.531286
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.220784
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1939484